VAHEBIO — Science · Longevity · Optimised
The Compendium

Weight Management

AOD-9604

Modified C-terminal fragment of human growth hormone marketed for lipolysis without GH side effects.

Half-life
Short (< 1 hour) in plasma.
Route
Subcutaneous, oral (limited bioavailability)

Overview

AOD-9604 is a synthetic fragment (176–191) of the human growth hormone molecule, developed by Metabolic Pharmaceuticals in Australia.

Mechanism of action

Retains the fat-metabolising region of GH — stimulating lipolysis and inhibiting lipogenesis — without the growth-promoting or insulin-antagonist actions of the full molecule.

Evidence base

Phase 2 trials in obesity showed modest weight loss (~2.6 kg over 12 weeks) that failed to distinguish from placebo. FDA granted GRAS status for oral use in 2014.

Typical dosing

Common protocol: 250–500 mcg subcutaneously daily, often in the morning fasted. Open the dose calculator →

Safety & contraindications

Well tolerated across trials; no significant impact on IGF-1 or glucose.

Related peptides

Semaglutide
Same class
Weight Management
Tirzepatide
Same class
Weight Management
Retatrutide
Same class
Weight Management
Adipotide
Same class
Weight Management

Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.